Sandoz announced the FDA approval and launch of Glatopa (glatiramer acetate injection) 40 mg/mL. Glatopa 40 mg/mL is a fully-substitutable, AP-rated generic version of Copaxone 40 mg/mL three times-a-week therapy for relapsing forms of multiple sclerosis.

Glatopa 40 mg/mL, along with Glatopa 20 mg/mL, will offer patients a complete range of dosing options. Glatopa 20 mg/mL was made available in the U.S. in June 2015. Patients can expect the same patient services for Glatopa 40 mg/mL as for Glatopa 20 mg/mL.

Sandoz GlatopaCare will offer a $0 co-pay support program to qualified patients. To help increase patient confidence with administering injections, patients will receive personalized injection training, 24-hour access to nurses for Glatopa-related questions and a free starter kit, which includes the Glatopaject injection device, designed to work with both Glatopa 20 mg/mL and 40 mg/mL prefilled syringes.